ReviewEuropean journal of immunology2025
VSTM1/SIRL-1: An Inhibitory Pattern Recognition Receptor Regulating Myeloid Cells.
Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structural diversity of lipid A modulates neutrophil proteome and secretome responses.Journal of proteomics · 2026Article
- SIRL-1 deficiency reveals pro-inflammatory IL-8 axis in inflammatory bowel disease: a novel diagnostic ratio.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate immune cells express a plethora of inhibitory receptors, many of which recognize molecular patterns. An appropriate balance between signaling via activating and inhibitory pattern recognition receptors is important for a proper immune response while preventing immunopathology. V-set and transmembrane domain containing 1 (VSTM1), also known as signal inhibitory receptor on leukocytes-1 (SIRL-1), is an inhibitory receptor expressed on myeloid cells. VSTM1 can modulate the function of myeloid cells, by inhibiting reactive oxygen species and neutrophil extracellular trap formation. VSTM1 recognizes shared molecular patterns both from endogenous and microbial origin, defining it as an inhibitory pattern recognition receptor. VSTM1 is involved in various pathological conditions, including autoimmune disorders and cancer, and its restricted expression on myeloid cells highlights its potential as a specific therapeutic target. This review summarizes the characteristics and function of VSTM1 in health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.